Abstract
Pathological tau protein is found in Alzheimer's disease and related tauopathies. The protein is hyperphosphorylated and/or mutated which leads to aggregation and neurotoxicity. Because cognitive functions correlate well with the degree of tau pathology, clearing these aggregates is a promising therapeutic approach. Studies pioneered by our laboratory and confirmed by others have shown that both active and passive immunizations targeting disease-related tau epitopes successfully reduce tau aggregates in vivo and slow or prevent behavioral impairments in mouse models of tauopathy. Here, we summarize recent advances in this new field.
Similar content being viewed by others
References
Andorfer C, Kress Y, Espinoza M, de Silva R, Tucker KL, Barde YA, Duff K, Davies P (2003) Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms. J Neurochem 86:582–590
Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT (1992) Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology 42:631–639
Asuni AA, Boutajangout A, Quartermain D, Sigurdsson EM (2007) Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. J Neurosci 27:9115–9129
Bard F et al (2000) Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 6:916–919
Bell RD, Zlokovic BV (2009) Neurovascular mechanisms and blood–brain barrier disorder in Alzheimer's disease. Acta Neuropathol 118:103–113
Boimel M, Grigoriadis N, Lourbopoulos A, Haber E, Abramsky O, Rosenmann H (2010) Efficacy and safety of immunization with phosphorylated tau against neurofibrillary tangles in mice. Exp Neurol 224:472–485
Boutajangout A, Ingadottir J, Davies P, Sigurdsson EM (2010a) Passive tau immunotherapy diminishes functional decline and clears tau aggregates in a mouse model of tauopathy. Alzheimers Dement 6:S578
Boutajangout A, Quartermain D, Sigurdsson EM (2010b) Immunotherapy targeting pathological tau prevents cognitive decline in a new tangle mouse model. J Neurosci 30:16559–16566
Boutajangout A, Ingadottir J, Davies P, Sigurdsson EM (2011) Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain. J Neurochem. doi:10.1111/j.1471-4159.2011.07337.x
Broadwell RD, Sofroniew MV (1993) Serum proteins bypass the blood–brain fluid barriers for extracellular entry to the central nervous system. Exp Neurol 120:245–263
Castillo DL, Lasagna-Reeves C, Guerrero-Munoz MJ, Estes DM, Barrett A, Dineley K, Jackson GR, Kayed R (2010) Modulation of tau oligomers by passive vaccination. Soc Neurosci Abstr 347.11
Clavaguera F, Bolmont T, Crowther RA, Abramowski D, Frank S, Probst A, Fraser G, Stalder AK, Beibel M, Staufenbiel M, Jucker M, Goedert M, Tolnay M (2009) Transmission and spreading of tauopathy in transgenic mouse brain. Nat Cell Biol 11:909–913
Das P, Howard V, Loosbrock N, Dickson D, Murphy MP, Golde TE (2003) Amyloid-beta immunization effectively reduces amyloid deposition in FcRγ−/− knock-out mice. J Neurosci 23:8532–8538
Delacourte A, Sergeant N, Champain D, Wattez A, Maurage CA, Lebert F, Pasquier F, David JP (2002) Nonoverlapping but synergetic tau and APP pathologies in sporadic Alzheimer's disease. Neurology 59:398–407
DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM (2001) Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A 98:8850–8855
Frautschy SA, Baird A, Cole GM (1991) Effects of injected Alzheimer β-amyloid cores in rat brain. Proc Natl Acad Sci U S A 88:8362–8366
Frost B, Jacks RL, Diamond MI (2009) Propagation of tau misfolding from the outside to the inside of a cell. J Biol Chem 284:12845–12852
Furlan R, Brambilla E, Sanvito F, Roccatagliata L, Olivieri S, Bergami A, Pluchino S, Uccelli A, Comi G, Martino G (2003) Vaccination with amyloid-β peptide induces autoimmune encephalomyelitis in C57/BL6 mice. Brain 126:285–291
Goedert M, Jakes R (2005) Mutations causing neurodegenerative tauopathies. Biochim Biophys Acta 1739:240–250
Gotz J, Chen F, Van Dorpe J, Nitsch RM (2001) Formation of neurofibrillary tangles in P301L tau transgenic mice induced by Aβ 42 fibrils. Science 293:1491–1495
Higuchi M (2011) Molecular mediators of amyloidosis-inflammation coupling in Alzheimer's disease: in vivo evidence in humans and animal models. Neurodegener Dis, 8(Suppl 1)
Holmes C, Boche D, Wilkinson D, Yadegarfar G, Hopkins V, Bayer A, Jones RW, Bullock R, Love S, Neal JW, Zotova E, Nicoll JAR (2008) Long-term effects of Aβ(42) immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 372:216–223
Janus C, Pearson J, McLaurin J, Mathews PM, Jiang Y, Schmidt SD, Chishti MA, Horne P, Heslin D, French J, Mount HT, Nixon RA, Mercken M, Bergeron C, Fraser PE, George-Hyslop P, Westaway D (2000) Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 408:979–982
Kerchner GA, Boxer AL (2010) Bapineuzumab. Expert Opin Biol Ther 10:1121–1130
Krishnamurthy PK, Deng Y, Mathews PM, Sigurdsson EM (2010) Mechanistic studies of antibody mediated clearance of tau aggregates using an ex vivo brain slice model. Alzheimers Dement 6:S276
Lemere CA, Masliah E (2010) Can Alzheimer disease be prevented by amyloid-β immunotherapy? Nat Rev Neurol 6:108–119
Lewis J, McGowan E, Rockwood J, Melrose H, Nacharaju P, Van Slegtenhorst M, Gwinn-Hardy K, Paul MM, Baker M, Yu X, Duff K, Hardy J, Corral A, Lin WL, Yen SH, Dickson DW, Davies P, Hutton M (2000) Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat Genet 25:402–405
Lewis J, Dickson DW, Lin WL, Chisholm L, Corral A, Jones G, Yen SH, Sahara N, Skipper L, Yager D, Eckman C, Hardy J, Hutton M, McGowan E (2001) Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 293:1487–1491
Mallery DL, McEwan WA, Bidgood SR, Towers GJ, Johnson CM, James LC (2010) Antibodies mediate intracellular immunity through tripartite motif-containing 21 (TRIM21). Proc Natl Acad Sci U S A 107:19985–19990
Masliah E, Rockenstein E, Adame A, Alford M, Crews L, Hashimoto M, Seubert P, Lee M, Goldstein J, Chilcote T, Games D, Schenk D (2005) Effects of α-synuclein immunization in a mouse model of Parkinson's disease. Neuron 46:857–868
Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardy J, Duff K, Jantzen P, DiCarlo G, Wilcock D, Connor K, Hatcher J, Hope C, Gordon M, Arendash GW (2000) Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408:982–985
Morgan D, Lee D, Brownlow M, Selenica M-L, Reid P, Alvarez J, Gordon MN (2011) Opposing roles of microglial activation in amyloid depositing and tau depositing transgenic mice. Neurodegener Dis, 8(Suppl 1)
Muhs A, Hickman DT, Pihlgren M, Chuard N, Giriens V, Meerschman C, van der Auwera I, van Leuven F, Sugawara M, Weingertner MC, Bechinger B, Greferath R, Kolonko N, Nagel-Steger L, Riesner D, Brady RO, Pfeifer A, Nicolau C (2007) Liposomal vaccines with conformation-specific amyloid peptide antigens define immune response and efficacy in APP transgenic mice. Proc Natl Acad Sci U S A 104:9810–9815
Nerenberg ST, Prasad R (1975) Radioimmunoassays for Ig classes G, A, M, D, and E in spinal fluids: normal values of different age groups. J Lab Clin Med 86:887–898
Novak M (2009) Tau vaccine: active immunization with misfolded tau protein attenuates tau pathology in the transgenic rat model of tauopathy. Alzheimers Dement 5:P93
Novak M (2010) Tau transgenic rat model and response to tau vaccine. Alzheimers Dement 6:S118
Orgogozo JM, Gilman S, Dartigues JF, Laurent B, Puel M, Kirby LC, Jouanny P, Dubois B, Eisner L, Flitman S, Michel BF, Boada M, Frank A, Hock C (2003) Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization. Neurology 61:46–54
Otvos L Jr, Feiner L, Lang E, Szendrei GI, Goedert M, Lee VM (1994) Monoclonal antibody PHF-1 recognizes tau protein phosphorylated at serine residues 396 and 404. J Neurosci Res 39:669–673
Pearson RCA, Powell TPS (1989) The neuroanatomy of Alzheimer's disease. Rev Neurosci 2:101–122
Polydoro M, Acker CM, Duff K, Castillo PE, Davies P (2009) Age-dependent impairment of cognitive and synaptic function in the htau mouse model of tau pathology. J Neurosci 29:10741–10749
Ribe EM, Perez M, Puig B, Gich I, Lim F, Cuadrado M, Sesma T, Catena S, Sanchez B, Nieto M, Gomez-Ramos P, Moran MA, Cabodevilla F, Samaranch L, Ortiz L, Perez A, Ferrer I, Avila J, Gomez-Isla T (2005) Accelerated amyloid deposition, neurofibrillary degeneration and neuronal loss in double mutant APP/tau transgenic mice. Neurobiol Dis 20:814–822
Roberson ED, Scearce-Levie K, Palop JJ, Yan FR, Cheng IH, Wu T, Gerstein H, Yu GQ, Mucke L (2007) Reducing endogenous tau ameliorates amyloid β-induced deficits in an Alzheimer's disease mouse model. Science 316:750–754
Rosenmann H, Grigoriadis N, Karussis D, Boimel M, Touloumi O, Ovadia H, Abramsky O (2006) Tauopathy-like abnormalities and neurologic deficits in mice immunized with neuronal tau protein. Arch Neurol 63:1459–1467
Schenk D et al (1999) Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400:173–177
Schindowski K, Bretteville A, Leroy K, Begard S, Brion JP, Hamdane M, Buee L (2006) Alzheimer's disease-like tau neuropathology leads to memory deficits and loss of functional synapses in a novel mutated tau transgenic mouse without any motor deficits. Am J Pathol 169:599–616
Siemers ER, Friedrich S, Dean RA, Gonzales CR, Farlow MR, Paul SM, DeMattos RB (2010) Safety and changes in plasma and cerebrospinal fluid amyloid β after a single administration of an amyloid β monoclonal antibody in subjects with Alzheimer disease. Clin Neuropharmacol 33:67–73
Sigurdsson EM (2009) Tau-focused immunotherapy for Alzheimer's disease and related tauopathies. Curr Alzheimer Res 6:446–450
Sigurdsson EM, Lorens SA, Hejna MJ, Dong XW, Lee JM (1996) Local and distant histopathological effects of unilateral amyloid-beta 25–35 injections into the amygdala of young F344 rats. Neurobiol Aging 17:893–901
Sigurdsson EM, Lee JM, Dong XW, Hejna MJ, Lorens SA (1997) Bilateral injections of amyloid-β 25-35 into the amygdala of young Fischer rats: behavioral, neurochemical, and time dependent histopathological effects. Neurobiol Aging 18:591–608
Sigurdsson EM, Scholtzova H, Mehta PD, Frangione B, Wisniewski T (2001) Immunization with a non-toxic/non-fibrillar amyloid-β homologous peptide reduces Alzheimer's disease associated pathology in transgenic mice. Am J Pathol 159:439–447
Sigurdsson EM, Knudsen E, Asuni A, Fitzer-Attas C, Sage D, Quartermain D, Goni F, Frangione B, Wisniewski T (2004) An attenuated immune response is sufficient to enhance cognition in an Alzheimer's disease mouse model immunized with amyloid-β derivatives. J Neurosci 24:6277–6282
Tampellini D, Magrane J, Takahashi RH, Li F, Lin MT, Almeida CG, Gouras GK (2007) Internalized antibodies to the Aβ domain of APP reduce neuronal Aβ and protect against synaptic alterations. J Biol Chem 282:18895–18906
Theunis C, Crespo Biel N, Borghgraef P, Devijver H, Gafner V, Philgren M, Hickman DT, Chuard N, Lopez Deber MP, Reis P, Buccarello AL, Adolfsson O, Pfeifer A, Muhs A, Van Leuven F (2011) Protein tau, target for immunotherapy: pre-clinical evaluation in transgenic mice. Neurodegener Dis, 8(Suppl 1)
Troquier L, Burnouf S, Belarbi K, Caillierez R, Blum D, Buee L (2011) Modulation of tau pathology in THY-Tau22 transgenic mice: from physical exercise to immunotherapy. Neurodegener Dis, 8(Suppl 1)
Wang A, Das P, Switzer RC III, Golde TE, Jankowsky JL (2011) Robust amyloid clearance in a mouse model of Alzheimer's disease provides novel insights into the mechanism of amyloid-β immunotherapy. J Neurosci 31:4124–4136
Wilcock GK, Esiri MM (1982) Plaques, tangles and dementia: a quantitative study. J Neurol Sci 56:343–356
Acknowledgments
This study is supported by NIH grants AG032611, AG020197, the Alzheimer's Association, the Alzheimer's Drug Discovery Foundation/Association for Frontotemporal Dementia, and the Irma T Hirschl/Monique Caulier Trust.
Disclosure
Patent is pending on tau immunotherapy.
Author information
Authors and Affiliations
Corresponding author
Additional information
Journal of Molecular Neuroscience - (Special Issue on 7th International Conference on Frontotemporal Dementias), in press, 2011. Guest Editor: Bernardino Ghetti, Editor-in-Chief: Illana Gozes
Rights and permissions
About this article
Cite this article
Gu, J., Sigurdsson, E.M. Immunotherapy for Tauopathies. J Mol Neurosci 45, 690–695 (2011). https://doi.org/10.1007/s12031-011-9576-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12031-011-9576-5